Recro Pharma (REPH), Idera Pharma (IDRA) will resume trading at 7:30am ET

Recro Pharma (REPH) Announces IV Meloxicam Phase 3 Met Primary Endpoint

Recro Pharma, Inc. (Nasdaq: REPH) announced positive results from its second of two Phase III clinical trials evaluating intravenous (IV) meloxicam for the treatment of acute postoperative pain. In this trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference (SPID) over the first 24 hours (SPID24), compared to placebo, in patients following abdominoplasty surgery. With the positive data from this study, the Company believes this completes the efficacy program for the IV meloxicam New Drug Application (NDA).

In this multicenter, randomized, double-blind, placebo-controlled clinical... More

Idera Pharma (IDRA), Vivelix Pharma Enter Exclusive IMO-9200 Licensing Agreement

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), and Vivelix Pharmaceuticals, Ltd., announced that they have entered into an exclusive license and collaboration agreement granting Vivelix worldwide rights to develop and market IMO-9200, an antagonist of TLR 7,8 and 9, for non-malignant gastrointestinal disorders. As part of the agreement, Idera has agreed to create and characterize potential back-up compounds for Vivelix.

We are excited to acquire an asset as innovative and... More

Recro Pharma (REPH) trading halted with news pending

Recro Pharma (NASDAQ: REPH) trading halted with news pending.